Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?

about

Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?

Item

http://www.wikidata.org/entity/Q57904857

description

im Januar 2006 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2006

@uk

name

Is there still place for VAD a ...... didates for high-dose therapy?

@en

Is there still place for VAD a ...... didates for high-dose therapy?

@nl

type

Item

label

Is there still place for VAD a ...... didates for high-dose therapy?

@en

Is there still place for VAD a ...... didates for high-dose therapy?

@nl

prefLabel

Is there still place for VAD a ...... didates for high-dose therapy?

@en

Is there still place for VAD a ...... didates for high-dose therapy?

@nl

P1476

Is there still place for VAD a ...... didates for high-dose therapy?

@en

P2860

Antitumor activity of thalidomide in refractory multiple myeloma.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Treatment of plasma cell dyscrasias with thalidomide and its derivatives.

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

VAD-based regimens as primary treatment for multiple myeloma.

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

P304

2271-2272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190600908620

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17107895

http://www.w3.org/2001/XMLSchema#string